Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 6, 2025American Journal of Hematology

CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

SKSwetha KambhampatiKAKwang Woo AhnJPJinalben Patel

Discussion

Loading...

Member takes

Overview

CIBMTR analysis shows effective CD19 CAR T therapy improves overall survival in relapsed transformed follicular lymphoma, indicating notable safety concerns.

Key Points

  • CD19 CAR T therapy is effective for relapsed/refractory transformed follicular lymphoma, achieving an overall response rate of 76%.
  • The 2-year overall survival rate after CAR T therapy was 57%, with progression-free survival at 43%.
  • Significantly, older patients aged 60 and above faced a higher risk of non-relapse mortality.
  • Grade ≥ 3 cytokine release syndrome and neurologic syndrome occurred in 7.1% and 21.6% of patients, indicating potential safety concerns.

Cite This Study

Kambhampati et al. (2025) studied this question.

synapsesocial.com/papers/689521f09f4f1c896c42888bhttps://doi.org/10.1002/ajh.70027
View Full Paper
Ask AI
Bookmark
Share